leadf
logo-loader
viewShield Therapeutics PLC
(
LSE:STXFRA:1JS
)

Shield Therapeutics says TEVA has withdrawn patent challenge

Shield’s general counsel, Lucy Huntington-Bailey, said: "We are delighted that the European Patent Office has decided not to continue proceedings following the withdrawal of the opposition by TEVA and saw no reason to amend the patent as originally granted. This publicly demonstrates the validity of the patent and the strength of defence that Shield provided to robustly defend its patents"      

Shield Therapeutics PLC -

Shield Therapeutics PLC (LON:STX) has confirmed that the generics giant Teva Pharmaceutical Industries has withdrawn its patent challenge, which had gone to the appeal stage.

The company said this means European Patent No.2668175, which covers the "process for preparing an iron hydroxypyrone" has become final and that the patent will be maintained as amended on March 14 last year.

Additionally, Teva's ending of its opposition to European Patent No.3160951 ("crystalline forms of ferric maltol") means the patent is maintained as granted, providing protection out to October 2035.

In a statement, Shield’s general counsel, Lucy Huntington-Bailey, said: "We are delighted that the European Patent Office has decided not to continue proceedings following the withdrawal of the opposition by TEVA and saw no reason to amend the patent as originally granted.

“This publicly demonstrates the validity of the patent and the strength of defence that Shield provided to robustly defend its patents."      

Shield is the developer of a stable, non-salt based orally taken treatment for adults with iron deficiency with or without anaemia called Feraccru here in the UK and Accrufer in the US.

Quick facts: Shield Therapeutics PLC

Follow
LSE:STX

Price: 39 GBX

Market Cap: £84.19 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

Shield Therapeutics' on cusp of US market expansion with focus on...

Shield Therapeutics PLC (LSE:STX, FRA:1JS)'s (LON:STX, OTCQX:SHIEF) investment case is presented by Proactive Research Analyst John Savin who explains how the firm hinges on the success of their US launch of commercialising Accrufer. This treatment is for iron deficiency or anaemia and as...

4 weeks, 1 day ago

2 min read